Posted in Abbott, Amgen, AstraZeneca, BMS, Bayer, Biotech, Celgene, Daiichi Sankyo, FDA, Forest Labs, GSK, Genentech, J&J, Johnson and Johnson, Lilly, Medical Devices, Medicine, Merck, Novartis, Pfizer, Pharma, Pharma News, Pharmaceutical, Red Cross, Sales training, Sanofi-Aventis, Statins, Takeda, tagged alimta, asco, Avastin, herceptin, Millennium, psoriasis, rad001, ranbaxy, s, trasylol, vaptan, vectibix, viagra, xience, zometa on May 16, 2008 | No Comments »
There’s a ton of stuff going on this week, plus we’re in pre-ASCO mode (so lots of oncology news - scroll down for those headlines). Here we go:
What’s a vaptan? Maybe something pretty exciting - A new class of drugs called vaptans may be able to treat a wide variety of conditions including painful periods, [...]
Read Full Post »
Posted in Abbott, Biotech, Cephalon, Healthcare, Medical Devices, Medicine, Merck, Novo Nordisk, Pharma, Pharma News, Pharmaceutical, tagged ADHD, Fentora, King Pharma, Medtronic, NovoSeven on May 12, 2008 | No Comments »
Merck the latest to make major cuts to its sales force - The unwinding of the Big Pharma sales armies continues apace, with Merck saying late today that it’s cutting its U.S. sales force by 1,200 positions, or about 14% from 8,500 reps at the start of 2007…more (and, in a strange twist, it appears [...]
Read Full Post »
Posted in Abbott, FDA, Forest Labs, GSK, Glaxosmithkline, Lilly, Medical Devices, Medicine, Merck, Novartis, Pfizer, Pharma, Pharma News, Pharmaceutical, Takeda, tagged drug reps, enbrel, Millennium, PDI, Pozen on April 18, 2008 | No Comments »
We are loaded up this week!
Can Enbrel reverse Alzheimers? - Alzheimer’s patients given a drug usually used to treat arthritis have shown dramatic improvements, leading to hopes of a breakthrough in treating the disease…more
Pfizer plunges on reduced profits - The pharmaceutical maker reported worse than expected results across the board in its first quarter, with [...]
Read Full Post »
Posted in Abbott, Cephalon, GSK, Glaxosmithkline, Merck, Pfizer, Pharma, Pharma News, Pharmaceutical, Schering, Takeda, tagged Spiriva, TAP, Treanda, vytorin, Zetia on March 22, 2008 | 1 Comment »
Cephalon’s Treanda approved for leukemia: Cephalon Inc. received clearance from regulators yesterday to begin selling Treanda as a treatment for a rare form of leukemia. The medicine will be a new option for about 15,000 people in the United States diagnosed annually with the slow-progressing form of leukemia known as chronic lymphocytic leukemia, or CLL.
The [...]
Read Full Post »
The rumor that has swirled around today appears to now be confirmed - Abbott and Takeda are going to divide up TAP.
Abbott Laboratories disclosed late Wednesday that it has agreed to with Japanese partner Takeda Pharmaceuticals to split up their decades-old drug-making joint venture, TAP Pharmaceuticals.
Takeda, Japan’s biggest drug producer, has long been interested in [...]
Read Full Post »
In my occasional series on how effectively pharma companies present themselves on their website home pages, today we arrive at Abbott labs (Abbott.com).
I will admit right off that I’ve never been a fan of the Abbott logo. I find it singularly uninspiring and I wish that a company that has so much going for it [...]
Read Full Post »
Posted in Abbott, Biotech, Celgene, GSK, Glaxosmithkline, Healthcare, J&J, Johnson and Johnson, Medical Devices, Novartis, Oncology, Pharma, Pharma News, Pharmaceutical, tagged natrecor, par-4, resveratrol, revlimid, sirtris, Tasigna, xience on November 29, 2007 | No Comments »
Glaxo buying Reliant - GlaxoSmithKline Plc has agreed to buy privately held heart drug specialist Reliant Pharmaceuticals for $1.65 billion in cash, in a move to boost its flagging drug sales in the United States…more
J&J says good-bye to $440 mil - Johnson & Johnson said on Thursday its fourth-quarter results would include a special after-tax, [...]
Read Full Post »
Posted in Abbott, BMS, Bayer, Merck, News, Novartis, Oncology, Pfizer, Pharma, Pharma News, Pharmaceutical, Sanofi-Aventis, Takeda on July 13, 2007 | 1 Comment »
Merck investing even more in its cancer portfolio - a growing trend among the top pharma companies.
Takeda seeking to grow its Amitiza franchise, now that Novartis’ Zelnorm has been pulled from the market.
Novartis gets approval for patch version of its Alzheimer’s drug Exelon.
More encouragement on the anti-blood-clotting front - BMS/Pfizer experimental drug apixaban meets goals [...]
Read Full Post »
